Marker Therapeutics (MRKR) Projected to Release Earnings on Thursday

Marker Therapeutics (NASDAQ:MRKR) is expected to post its Q3 2026 resultson Thursday, November 12th. Analysts expect Marker Therapeutics to post earnings of ($0.1167) per share and revenue of $2.12 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Marker Therapeutics (NASDAQ:MRKR) last announced its earnings results on Friday, August 14th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.16. On average, analysts expect Marker Therapeutics to post ($0.64) EPS for the current fiscal year and ($1.23) EPS for the next fiscal year.

Marker Therapeutics Price Performance

NASDAQ MRKR opened at $0.99 on Tuesday. The business’s fifty day moving average price is $1.08 and its 200-day moving average price is $1.34. The stock has a market capitalization of $16.51 million, a price-to-earnings ratio of -2.42 and a beta of 1.65. Marker Therapeutics has a 1-year low of $0.84 and a 1-year high of $2.46.

Analyst Ratings Changes

Several analysts recently commented on MRKR shares. Zacks Research raised Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 15th. HC Wainwright reissued a “buy” rating on shares of Marker Therapeutics in a report on Friday, August 21st. Finally, Weiss Ratings raised Marker Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 19th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Marker Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s platform is designed to produce multi-antigen-targeted T cells, which recognize several tumor-associated antigens rather than a single target. Marker Therapeutics has been developing these therapies for use in patients with hematologic malignancies and solid tumors.

The company’s investigational pipeline has included MT-601, an autologous multiTAA-specific T-cell therapy being evaluated for certain solid tumors, and MT-401, a related therapy developed for acute myeloid leukemia.